Search Results

Filter
  • 1-10 of  285,768 results for "%22ANTIVIRAL agents%22"
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.

  • Authors : Hammond J; From Global Product Development, Pfizer, Collegeville, PA (J.H.); Global Product Development, Pfizer, Groton, CT (R.J.F.)

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/adverse effects ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; COVID-19*/COVID-19*/COVID-19*/diagnosis

  • Source: The New England journal of medicine [N Engl J Med] 2024 Apr 04; Vol. 390 (13), pp. 1186-1195.Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients.

  • Authors : Hou J; Nanfang Hospital, Southern Medical University, Guangzhou, China.; Gane E

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/adverse effects ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/drug therapy

  • Source: Clinical and molecular hepatology [Clin Mol Hepatol] 2024 Apr; Vol. 30 (2), pp. 191-205. Date of Electronic Publication: 2024 Jan 08.Publisher: Korean Association for the Study of the Liver Country of Publication: Korea (South) NLM ID: 101586730 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level in vivo is dependent on de novo core protein translation.

  • Authors : Berke JM; Infectious Diseases Discovery, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.; Tan Y

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Apoptosis*/Apoptosis*/Apoptosis*/drug effects

  • Source: Journal of virology [J Virol] 2024 Mar 19; Vol. 98 (3), pp. e0150223. Date of Electronic Publication: 2024 Feb 05.Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

The 25-kDa linear polyethylenimine exerts specific antiviral activity against pseudorabies virus through interferencing its adsorption via electrostatic interaction.

  • Authors : Huan C; Institute of Agricultural Science and Technology Development, College of Veterinary Medicine, Yangzhou University, Yangzhou, China.; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China.

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/chemistry ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Herpesvirus 1, Suid*/Herpesvirus 1, Suid*/Herpesvirus 1, Suid*/drug effects

  • Source: Journal of virology [J Virol] 2024 Mar 19; Vol. 98 (3), pp. e0000724. Date of Electronic Publication: 2024 Feb 02.Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus .

  • Authors : Cross RW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

Subjects: Ebolavirus*/Ebolavirus*/Ebolavirus*/drug effects ; Hemorrhagic Fever, Ebola*/Hemorrhagic Fever, Ebola*/Hemorrhagic Fever, Ebola*/drug therapy ; Hemorrhagic Fever, Ebola*/Hemorrhagic Fever, Ebola*/Hemorrhagic Fever, Ebola*/prevention & control

  • Source: Science (New York, N.Y.) [Science] 2024 Mar 15; Vol. 383 (6688), pp. eadk6176. Date of Electronic Publication: 2024 Mar 15.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic

Record details

×
Academic Journal

An oral antiviral for Ebola disease.

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/administration & dosage ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Ebolavirus*/Ebolavirus*/Ebolavirus*/drug effects

  • Source: Science (New York, N.Y.) [Science] 2024 Mar 15; Vol. 383 (6688), pp. 1181-1182. Date of Electronic Publication: 2024 Mar 14.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic

Record details

×
Academic Journal

Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376.

  • Authors : Lin C; College of Pharmacy, Gannan Medical University, Ganzhou 341000, China.; Zhu Z

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/chemistry ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Coronavirus*/Coronavirus*/Coronavirus*/drug effects SARS-CoV-2 variants

  • Source: Journal of molecular biology [J Mol Biol] 2024 Mar 15; Vol. 436 (6), pp. 168474. Date of Electronic Publication: 2024 Feb 02.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 2985088R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges.

  • Authors : Du S; Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR China.; Hu X

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/metabolism

  • Source: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy [Drug Resist Updat] 2024 Mar; Vol. 73, pp. 101053. Date of Electronic Publication: Publisher: Churchill Livingstone Country of Publication: Scotland NLM ID: 9815369 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.

  • Authors : Tong K; Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.; Chen M

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/therapeutic use ; Hepatitis B, Chronic*/Hepatitis B, Chronic*/Hepatitis B, Chronic*/drug therapy; Humans

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Mar; Vol. 80 (3), pp. 335-354. Date of Electronic Publication: 2024 Jan 10.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041

Record details

×
Academic Journal

Developments in the chemistry and biology of 1,2,3-triazolyl-C-nucleosides.

  • Authors : Nascimento SMRD; Biocatalysis and Organic Synthesis Group, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.; Ferry A

Subjects: Nucleosides*/Nucleosides*/Nucleosides*/pharmacology ; Nucleosides*/Nucleosides*/Nucleosides*/chemistry ; Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/pharmacology

  • Source: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2024 Mar; Vol. 357 (3), pp. e2300580. Date of Electronic Publication: 2023 Dec 27.Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
  • 1-10 of  285,768 results for "%22ANTIVIRAL agents%22"